JJP Biologics

𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗧𝗮𝗹𝗸: 𝗖𝗿𝗮𝗰𝗸𝗶𝗻𝗴 𝘁𝗵𝗲 𝗖𝗼𝗱𝗲 – 𝗧𝗵𝗲 𝗙𝗼𝘂𝗻𝗱𝗲𝗿'𝘀 𝗠𝗶𝗻𝗱𝘀𝗲𝘁 I will have the pleasure of exploring the topic with: Louis Boon, PhD – JJP Biologics – A powerhouse of biotech leadership, known for turning bold ideas into groundbreaking science. If there’s anyone who knows how to shape up the industry, it’s him. What does it really take to lead in biotech? Innovation is just the starting point - what truly defines successful biotech leaders is a bold vision, resilience, and the ability to make strategic, high-impact decisions. At #CEBioForum2025, I’m thrilled to host an exclusive leadership discussion where we’ll dive deep into how biotech founders and executives navigate scientific breakthroughs, investor expectations, and patient needs - all while shaping the future of #biotech and #healthcare. What’s on the agenda? 💡 The founder’s mindset – How to lead with vision & #resilience 🧬 Sustaining innovation – What sets top biotech leaders apart? 📊 Balancing stakeholders – Patients, investors, and R&D progress ⚖️ Making impactful decisions – Where do #biotech founders create the most value? 📅 Date & Time: April 2, 2025 | 12:30 - 13:00 📍 Location: Cambridge Innovation Center, Warsaw 🔗 Join us at CEBioForum 2025 and be part of the conversation! 👉 Secure your spot now https://lnkd.in/dhJBGPca Looking forward to insightful discussions—see you there! Central European BioForum ExecMind. Life Science Executive Search

JJP Biologics CSO and founder Dr. Louis Boon will share our incredible journey and how to build a PURPOSE-driven company. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #JJP1008, #SMARTGOOSE

Ciao Milan! Sandra Lampkowska, Pawel Szczepanski and Jurre Jansma of the JJP Biologics at a near-ending #BIOEuropeSpring had fruitful discussions exploring partnering opportunities to bring JJP Biologics' transformative therapies to patients worldwide. #ABM #innovation #partnering

Only 2 weeks to go

During the first months of 2025 JJP Biologics has focused their scientific series on the involvement of IgA in liver diseases. The post of the last couple of weeks were centralised around the accumulating evidence of IgA autoantibodies in the disease severity of primary sclerosing cholangitis patients. The current manuscript shows that serum IgA levels were elevated more frequently in patients with NASH compared with subjects with simple steatosis (55% vs. 31%, p <0.001). Overall, 55 (19%) patients had advanced liver fibrosis (Kleiner stage 3–4). There was a significant positive association between serum IgA levels and the stage of fibrosis (p <0.001). https://lnkd.in/dhJ6txxA As the liver is highly perfused, CD89-expressing peripheral neutrophils and monocytes can enter the liver through the systemic circulation. Furthermore locally already present CD89-expressing Kupffer cells as resident immune cells in the liver will be activated by these IgA autoantibodies. The effector functions of these CD89 bearing immune cells cause pathogenic inflammation and damage. JJP-1212 is an antagonist anti-CD89 antibody that prevents these IgA autoantibodies to activate CD89-expressing immune cells and will prevent the pathological damage to the liver mediated through this pathway. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology,#JJP1212, #SMARTGOOSE

JJP Biologics is very pleased to announce that Anna Łosińska finalised her immune-oncology HMX course to support the development of JJP-1008 but also to boost her personal development. We are exited that bright young people, like Anna Łosińska, are joining and contributing the amazing journey of JJP Biologics.

The 14th PHARM Connect Congress wrapped up last week where JJP Biologics CSO Dr. Louis Boon chaired day 1 and held the opening keynote lecture. Presenting the big WHY for drug developers, using a SMART GOOSE route to the destination. It is not a race from milestone to milestone rather a lifestyle. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology, #JJP1212, #SMARTGOOSE

🔵 March is Colorectal Cancer Awareness Month 🔵 Colorectal cancer is the second deadliest cancer in the U.S. and a major global health challenge. Every year: 📌 1.9 million new cases are diagnosed worldwide 📌 900,000+ lives are lost to the disease 📌 In Europe alone, 400,000 people receive a colorectal cancer diagnosis, and 180,000 do not survive Despite these alarming statistics, colorectal cancer is highly preventable and treatable when detected early. Screening saves lives, and raising awareness is crucial in the fight against this disease. At JJP Biologics, we are committed to advancing innovative treatments for unmet medical needs. Our JJP-1008 program is a first-in-class immune checkpoint inhibitor that targets cancers with high CD270 expression, including colorectal cancer. This novel approach offers hope for patients who do not respond to PD-L1 inhibitors. The JJP-1008 project is co-financed by the Polish Medical Research Agency, highlighting the power of collaboration in driving life-saving innovations. Together, we can push the boundaries of cancer treatment and work toward a future where more patients thrive beyond their diagnosis. #ColorectalCancerAwareness #ABM #JJPBiologics #Immunotherapy #CancerResearch

🚀 Pushing Boundaries in Biotech – The JJP Biologics Story 🔬✨ At JJP Biologics, we are driven by a singular purpose: developing innovative monoclonal antibody therapies and companion diagnostics to transform the lives of patients with cancer, autoimmune, and fibrotic diseases. Our journey, powered by world-class scientific expertise and a strong international collaboration network, has led to groundbreaking achievements in the Polish biotech sector: 🔹 JJP-1212 (anti-CD89) – The first innovative biological therapy in Poland to enter clinical trials, targeting IgA-driven autoimmune and fibrotic diseases. 🔹 JJP-1008 (anti-CD270) – A next-generation checkpoint inhibitor empowering the immune system to fight cancer. 🔹 Orphan Drug Designation & Clinical Trial Success – Achieving Phase I approval three years after founding. To drive next-level innovation, we're expanding our research laboratory, strengthening our expertise in protein engineering, structural biology, and recombinant protein expression. Our commitment is clear: delivering life-changing therapies for patients with unmet needs. 🎥 Watch our story unfold in the video below and join us on this mission! #Biotech #Innovation #Cancer #autoimmunity #ABM

Now that 2025 has started JJP Biologics will continue to create awareness about the critical involvement of IgA (auto)antibodies in several disease areas. Whereas in 2024 series of posts showing the involvement of IgA autoantibodies in autoimmune and fibrotic diseases, like Rheumatoid Arthritis, Lung diseases and neuro-inflammation, the current series will focus on the involvement of IgA in liver diseases. The results of the current manuscript show that a majority of investigated PSC patients had autoreactive IgA against biliary epithelial cells, whereas these antibodies were almost absent in healthy individuals. Furthermore, the levels of autoreactive IgA correlated with higher total serum IgA levels and autoreactive IgA-positive patients progressed faster to a clinical endpoint (death or liver transplantation) compared to autoreactive IgA-negative patients. These findings show the role of IgA in PSC patients and opens up for future studies addressing pathogenic mechanisms of autoantibodies directed against biliary epithelial cells. https://lnkd.in/e_8ePErm Increasing evidence points to an involvement of neutrophils and monocytes (which all express CD89) in chronic liver inflammation and cirrhosis. Interestingly, granulocyte and monocyte adsorptive apheresis has high efficacy for intestinal lesions and improves alkaline phosphatase and aspartate transaminase levels (high levels are a poor prognosis factor). Adsorptive apheresis appears to be a treatment option in patients with PSC associated with ulcerative colitis pointing to a central role of these activated myeloid lineage leukocytes from peripheral blood. As the liver is highly perfused, CD89-expressing peripheral neutrophils and monocytes can enter the liver through the systemic circulation. Furthermore locally already present CD89-expressing Kupffer cells as resident immune cells in the liver will be activated by these IgA autoantibodies. The effector functions of these CD89 bearing immune cells cause pathogenic inflammation and damage. JJP-1212 is an antagonist anti-CD89 antibody that prevents these IgA autoantibodies to activate CD89-expressing immune cells and will prevent the pathological damage to the liver mediated through this pathway. Stay tuned with JJP Biologics and follow us here on LinkedIn. Be a smart goose 🎆🎆 https://lnkd.in/eZV3ZbS9 #ABM, #biotechnology,#JJP1212, #SMARTGOOSE